Advertisement
Advertisement
TGTX
TG Therapeutics, Inc.
53.04
USDSponsored
-0.96
-1.78%
Sep 15, 16:00 UTC -4
Closed
After-Market
52.50
-0.54
-1.02%
TGTX Earnings Reports
Positive Surprise Ratio
TGTX beat 12 of 43 last estimates.
28%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$252.00M
/$0.36
Implied change from Q2 26 (Revenue/ EPS)
+4.86%
/+620.00%
Implied change from Q3 25 (Revenue/ EPS)
+55.84%
/+125.00%
TG Therapeutics, Inc. earnings per share and revenue
On Aug 03, 2026, TGTX reported earnings of 0.05 USD per share (EPS) for Q2 26, missing the estimate of 0.34 USD, resulting in a -85.48% surprise. Revenue reached 240.34 million, compared to an expected 234.32 million, with a 2.57% difference. The market reacted with a -11.26% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 9 analysts forecast an EPS of 0.36 USD, with revenue projected to reach 252.00 million USD, implying an increase of 620.00% EPS, and increase of 4.86% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Attovia Therapeutics, Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$2.78
Actual
-$4.88
Surprise
-75.25%
Scribe Therapeutics Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$3.03
Actual
-$2.62
Surprise
+13.59%
enGene Therapeutics Inc. Common Stock
Report Date
Sep 08, 2026 For Q3 26
Estimate
-$0.43
Actual
-$0.47
Surprise
-7.16%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Immutep Limited - ADR
Report Date
Sep 01, 2026 For Q4 26
Estimate
$0.00
Actual
-$0.02
Surprise
-2,500.00%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were TG Therapeutics, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, TG Therapeutics, Inc. reported EPS of $0.05, missing estimates by -85.48%, and revenue of $240.34M, 2.57% above expectations.
How did the market react to TG Therapeutics, Inc.'s Q2 2026 earnings?
The stock price moved down -11.26%, changed from $52.03 before the earnings release to $46.17 the day after.
When is TG Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for TG Therapeutics, Inc.'s next earnings report?
Based on 9
analysts, TG Therapeutics, Inc. is expected to report EPS of $0.36 and revenue of $252.00M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.